Joan Albertí

479 total citations
17 papers, 359 citations indexed

About

Joan Albertí is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Joan Albertí has authored 17 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Pharmacology and 3 papers in Oncology. Recurrent topics in Joan Albertí's work include Pharmacogenetics and Drug Metabolism (4 papers), Analytical Chemistry and Chromatography (3 papers) and Asthma and respiratory diseases (3 papers). Joan Albertí is often cited by papers focused on Pharmacogenetics and Drug Metabolism (4 papers), Analytical Chemistry and Chromatography (3 papers) and Asthma and respiratory diseases (3 papers). Joan Albertí collaborates with scholars based in Spain, United Kingdom and United States. Joan Albertí's co-authors include Sònia Sentellas, Oriol Morales‐Ibanez, Míriam Zanuy, Montserrat Miralpeix, Israel Ramos, Amadeu Gavaldà, Jörge Beleta, Javier Saurina, Elena Calama and Mònica Aparici and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry and European Respiratory Journal.

In The Last Decade

Joan Albertí

17 papers receiving 351 citations

Peers

Countries citing papers authored by Joan Albertí

Since Specialization

Citations

This map shows the geographic impact of Joan Albertí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Albertí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Albertí more than expected).

Fields of papers citing papers by Joan Albertí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Albertí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Albertí. The network helps show where Joan Albertí may publish in the future.

Co-authorship network of co-authors of Joan Albertí

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Albertí. A scholar is included among the top collaborators of Joan Albertí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Albertí. Joan Albertí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases 2022 ·International Immunopharmacology ·(unknown), Joan Albertí, Elsa Mondou, (unknown), (unknown), (unknown), Antonio Páez	3
2	A Novel, Extremely Bioavailable Cocrystal of Pterostilbene 2021 ·Crystal Growth & Design ·(unknown), Rafael Barbas, (unknown), Mercè Font-Bardı́a, Clara Ràfols, Joan Albertí, Rafel Prohens	27
3	Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases 2019 ·Journal of Medicinal Chemistry ·Jordi Bach, Paul Eastwood, (unknown), Elena Gómez, (unknown), Sı́lvia Fonquerna, (unknown), Adela Orellana, Mónica Maldonado, (unknown), Joan Albertí, Juan L. Barja, (unknown), Neus Prats, Cristina Carreño, Elena Calama, Jorge De Alba, Marta Calbet, Montserrat Miralpeix, Isabel Ramis	25
4	Final report of a phase I study of 2-hydroxyoleic acid (2OHOA) a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including recurrent high grade gliomas (rHGG). 2017 ·Journal of Clinical Oncology ·Analía Azaro, Elizabeth Ruth Plummer, Ander Urruticoechea, Jordi Rodón, (unknown), Gareth J. Veal, Antoine Périer, (unknown), Pablo V. Escribá, Xavier Busquets, Joan Albertí, Elisabet Sicart, Dearbhaile Catherine Collins, Ricardo Fernández, (unknown), E. Klumper, Juanita Lopez	8
5	Liquid chromatography-mass spectrometry as a general approach for investigating covalent binding of drugs to DNA 2016 ·Analytical and Bioanalytical Chemistry ·(unknown), Joan Albertí, Javier Saurina, Sònia Sentellas	2
6	New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats 2014 ·European Respiratory Journal ·Isabel Ramis, Elena Calama, (unknown), Cristina Carreño, (unknown), (unknown), Joan Albertí, Jorge De Alba, Jordi Bach, Neus Prats, Montserrat Miralpeix	1
7	The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide 2014 ·Pulmonary Pharmacology & Therapeutics ·Amadeu Gavaldà, Israel Ramos, (unknown), Elena Calama, (unknown), J.L. Montero, Sònia Sentellas, Mònica Aparici, Dolors Vilella, Joan Albertí, Jörge Beleta, Montserrat Miralpeix	40
8	GSSG/GSH ratios in cryopreserved rat and human hepatocytes as a biomarker for drug induced oxidative stress 2014 ·Toxicology in Vitro ·Sònia Sentellas, Oriol Morales‐Ibanez, Míriam Zanuy, Joan Albertí	83
9	Characterization of in vitro metabolic profiles of cinitapride obtained with liver microsomes of humans and various mammal species using UHPLC and chemometric methods for data analysis 2012 ·Analytical and Bioanalytical Chemistry ·(unknown), Joan Albertí, (unknown), Javier Saurina, Sònia Sentellas	4
10	Determination of S-containing drug metabolites from in vitro and in vivo metabolism studies by using LC-ICP/MS 2012 ·Analytical and Bioanalytical Chemistry ·Cristina Losada, Joan Albertí, Javier Saurina, Sònia Sentellas	12
11	Development of a UHPLC method for the assessment of the metabolic profile of cinitapride 2011 ·Journal of Separation Science ·(unknown), Joan Albertí, (unknown), Javier Saurina, Sònia Sentellas	11
12	Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A2B adenosine receptor antagonists 2010 ·Bioorganic & Medicinal Chemistry Letters ·Paul Eastwood, (unknown), Sergio Paredes, Arsenio Nueda, Teresa Domènech, Joan Albertí, Bernat Vidal	16
13	In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: Identification of the human enzymes involved in its oxidative metabolism 2010 ·Biochemical Pharmacology ·Joan Albertí, Sònia Sentellas, (unknown)	12
14	Identification of the Human Enzymes Responsible for the Enzymatic Hydrolysis of Aclidinium Bromide 2010 ·Drug Metabolism and Disposition ·Joan Albertí, (unknown), Sònia Sentellas, (unknown)	34
15	Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: In vitro plasma inactivation and pharmacological activity of its main metabolites 2010 ·European Journal of Pharmaceutical Sciences ·Sònia Sentellas, Israel Ramos, Joan Albertí, (unknown), (unknown), Montserrat Miralpeix, Jörge Beleta, Amadeu Gavaldà	65
16	Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A_2B Adenosine Receptor Antagonist 2010 ·ACS Medicinal Chemistry Letters ·Paul Eastwood, (unknown), (unknown), Sı́lvia Fonquerna, Josep Aiguadé, (unknown), Teresa Domènech, Mònica Aparici, Montserrat Miralpeix, Joan Albertí, (unknown), Raquel M. Fernández, (unknown), Núria Godessart, Neus Prats, Marı́a Isabel Loza, Marı́a Isabel Cadavid, Arsenio Nueda, Bernat Vidal	15
17	Enzymatic Hydrolysis of Aclidinium Bromide in Human Plasma by Human Esterases. 2009 ·Joan Albertí, (unknown), Sònia Sentellas, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact